UNSPSC 51343508: Tenofovir alafenamide

This classification denotes a reverse transcriptase inhibitor and purine antagonist C21H29N6O5P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EL9943AG5J, chemically known as l-alanine, n-((s)-(((1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)phenoxyphosphinyl)-, 1-methylethyl ester, but more generally known as tenofovir alafenamide, which bears US NIH Compound Identifier 9574768. Most nations, for tariff and trade purposes, schedule tenofovir alafenamide under HS 29335995 and SITC 51576.

As of Q4 2014, TENOFOVIR ALAFENAMIDE remains US FDA's Preferred Term for this commodity. SMILES: C[C@H](CN1CNC2C1NCNC2N)OC[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3CCCCC3.

UNSPSC 51343508 Tenofovir alafenamide is a Commodity code nominally for a specific HIV pharmaceutical, but recent state and local solicitations tagged under this code show little alignment with that product scope. The most active opportunities involve medical and first aid supplies, naloxone and drug deactivation systems, generic pharmaceuticals through cooperative purchasing, and exploratory direct-to-manufacturer pharmacy programs. State and local governments buying under this code—or at least those opportunities cross-tagged to it—include county health departments, municipal fire departments, state HHS agencies, and multistate cooperative purchasing organizations. The work ranges from emergency response consumables (respiratory equipment, cardiac monitoring supplies, endotracheal tubes, bandages) to broader pharmaceutical acquisition frameworks negotiated with wholesalers and manufacturers.

Recent opportunities span Florida, Texas, Minnesota, and Oregon. The City of Tampa issued an IFB for medical and first aid supplies for its Fire Department Rescue Division (Bid 26-P-00145, due March 13, 2026), with an estimated contract value of $700,000 and a sheltered-market designation for certified Small Local Business Enterprises. Seminole County, Florida posted an IFB for naloxone and drug deactivation systems (IFB60459723LAS, due July 26, 2023) requiring quarterly deliveries to its Community Health Building. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative purchasing vehicle, issued an RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026) serving multiple state and local facilities. The Texas Health and Human Services Commission issued a Request for Information on direct-to-manufacturer prescription programs (HHS0017013, due April 3, 2026) to inform future formal procurement strategy. The code shows fragmented issuing-body activity across counties, cities, and state agencies using both direct procurement and cooperative purchasing structures, though the recent opportunities as tagged do not consistently align with the code's nominal pharmaceutical scope.